The efficacy of PARP inhibitors for tuft cell-like SCLC was also recently proposed and discussed (e.g., concerning SLFN11, a biomarker of PARP inhibition [36, 46–50]) [12], but is not fully understood. This evidence concerns the gene PARP1 and small cell lung carcinoma.